References in periodicals archive ?
Timothy Block, President, Hepatitis B Foundation / IHVR and PA Biotechnology Center; and Professor and Director, Drexel Institute for Biotechnology and Virology Research of Drexel University College of Medicine welcomed more than 100 of the area's leading life sciences and biotech entrepreneurs.
The lead scientist for the new HCV drug is Michael Soffia, PhD, a professor with the Hepatitis B Foundation / IHVR, and also a co-founder with Higgins and Bryce Roberts in a new company focused on liver and infectious diseases called OnCore Biopharma.
“HCC is unfortunately very resistant to chemotherapy, leaving most patients with few therapeutic options,” said Timothy Block, Ph.D., co-founder and volunteer president of the Hepatitis B Foundation and IHVR. “A prototype of the compound we are developing has already proven effective in an animal model.
“The Hepatitis B Foundation and IHVR are extremely grateful to Pennsylvania and the CURE program for awarding grant funds to further this critical research.”
Acronyms browser ?
Full browser ?